Amarin Corporation PLC
AMRN
查看详细走势图
13.935USD
+0.335+2.46%
交易中 （美东）报价延迟15分钟
289.82M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.46%
5天
-1.45%
1月
-14.93%
6月
+11.12%
今年开始到现在
+43.66%
1年
+51.47%
查看详细走势图
TradingKey Amarin Corporation PLC股票评分
单位: USD 更新时间: 2025-12-22操作建议
Amarin Corporation PLC当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名125/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价12.00。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Amarin Corporation PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
持有
评级
12.000
目标均价
-19.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Amarin Corporation PLC亮点
亮点风险
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corporation PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Amarin Corporation PLC简介
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
公司代码AMRN
公司Amarin Corporation PLC
CEOBerg (Aaron D)
网址https://amarincorp.com/
常见问题
Amarin Corporation PLC(AMRN)的当前股价是多少？
Amarin Corporation PLC(AMRN)的当前股价是 13.935。
Amarin Corporation PLC的股票代码是什么？
Amarin Corporation PLC的股票代码是AMRN。
Amarin Corporation PLC股票的52周最高点是多少？
Amarin Corporation PLC股票的52周最高点是20.900。
Amarin Corporation PLC股票的52周最低点是多少？
Amarin Corporation PLC股票的52周最低点是7.080。
Amarin Corporation PLC的市值是多少？
Amarin Corporation PLC的市值是289.82M。
Amarin Corporation PLC的净利润是多少？
Amarin Corporation PLC的净利润为-82.18M。
现在Amarin Corporation PLC(AMRN)的股票是买入、持有还是卖出？
根据分析师评级，Amarin Corporation PLC(AMRN)的总体评级为持有，目标价格为12.000。
Amarin Corporation PLC(AMRN)股票的每股收益（EPS TTM）是多少
Amarin Corporation PLC(AMRN)股票的每股收益（EPS TTM）是-4.178。
相关品种
